Thomas Jefferson University
Social media success requires good branding, taking ‘a leap of faith’
Social media can be leveraged to broaden the reach of both yourself and your practice; achieving success requires shifting to a communications and public relations mindset, according to a presentation at GI Outlook.
Presence of orthopedic trainee does not impact patient-reported outcomes in spine surgery
Thyroid cancer specialist joins Sidney Kimmel Cancer Center at Jefferson
Sidney Kimmel Cancer Center — Jefferson Health appointed Marcia Brose, MD, PhD, vice chair of medical oncology and regional chief of cancer services at Jefferson Torresdale Hospital.
Medtronic names Austin L. Chiang first chief medical officer for GI business
Medtronic appointed Austin L. Chiang, MD, MPH, of Sidney Kimmel Medical College and chief medical social media officer and director of the endoscopic bariatric program at Thomas Jefferson University, chief medical officer of gastrointestinal business.
Transitions of care clinic improves 30-day stroke outcomes
Use of a transitions of care clinic may reduce 30-day stroke readmissions, according to findings presented at the American Neurological Association annual meeting.
Mortality on ECMO higher in second wave of patients with COVID-19
Mortality on extracorporeal membrane oxygenation was higher in the second wave of patients with COVID-19, despite improvements in treatment before ECMO initiation, according to data presented at the CHEST Annual Meeting.
Neurosurgery society endorses laser therapy for drug-resistant epilepsy
Tranexamic acid in TJA reduced complications in patients with preoperative coagulopathy
According to published results, tranexamic acid administration reduced intraoperative blood loss and decreased the risk of 90-day complications for patients with preoperative coagulopathy who underwent total hip or knee arthroplasty.
Orthopedic specialty hospitals are associated with lower rates of surgical site infection
Compared with tertiary care institutions, orthopedic specialty hospitals are associated with lower rates of deep surgical site infection at 1 year, according to published results.
Top in hem/onc: Phase 3 data on lung cancer therapy, new leadership at Mayo Clinic
Results of the GEMSTONE-301 study showed that sugemalimab was well tolerated and effective in patients with stage III non-small cell lung cancer. It was the top story in hematology/oncology last week.